Drug intelligence / Profile preview

ISIS-GSK4-LRx

Development stage: Unknown
Lead developer: Ionis Pharmaceuticals
Modality: Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics

Overview

ISIS-GSK4-LRx is an investigational antisense oligonucleotide (ASO) developed by ISIS Pharmaceuticals in collaboration with GSK. It targets an undisclosed mechanism, potentially related to liver or inflammatory pathways given the GSK partnership and naming convention, but specific details on mechanism of action, primary indication, or clinical outcomes are not publicly detailed beyond early Phase 1 initiation. The program earned GSK milestone payments for advancing to Phase 1 studies as part of a broader collaboration on multiple ASOs.[3][11]

Beyond the preview

Go deeper on ISIS-GSK4-LRx.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISIS-GSK4-LRx.

Explore the full profile